Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026
Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company Medical Device

Acotec Scientific’s Vericor Catheter Wins NMPA Approval for Peripheral Vascular Surgery

Fineline Cube Feb 25, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that its peripheral disposable support catheter Vericor...

Drug

CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study

Fineline Cube Feb 25, 2025

China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...

Company Drug

Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US

Fineline Cube Feb 25, 2025

Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...

Company

CDE Includes Chiral Tech’s Cerdelga Generic in Rare Disease Care Plan

Fineline Cube Feb 25, 2025

China’s Center for Drug Evaluation (CDE) announced the inclusion of Beijing Chiral Tech’s generic version...

Company Medical Device

Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment

Fineline Cube Feb 25, 2025

US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration...

Legal / IP

SMPA Suspends Indobufen Procurement After Patent Infringement Verdict

Fineline Cube Feb 25, 2025

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by...

Company Drug

Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study

Fineline Cube Feb 25, 2025

Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment

Fineline Cube Feb 25, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...

Company Drug

Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia

Fineline Cube Feb 25, 2025

Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...

Company Deals

Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors

Fineline Cube Feb 25, 2025

Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...

Company

Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M

Fineline Cube Feb 25, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer

Fineline Cube Feb 25, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...

Company Drug

CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine

Fineline Cube Feb 25, 2025

China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...

Company Deals

MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil

Fineline Cube Feb 25, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...

Company Drug

Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment

Fineline Cube Feb 25, 2025

Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...

Company Drug

QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study

Fineline Cube Feb 25, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...

Company Drug

Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients

Fineline Cube Feb 25, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...

Policy / Regulatory

National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details

Fineline Cube Feb 24, 2025

The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...

Company

Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology

Fineline Cube Feb 24, 2025

French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...

Company Drug

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China

Fineline Cube Feb 24, 2025

Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...

Posts pagination

1 … 185 186 187 … 644

Recent updates

  • Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic
  • Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
  • Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures
  • Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Company Medical Device

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.